GAST120 - Gastric Protective Gum with Controlled Ozone Release - 250 ml

GAST120 ACTIVOZONE

Is a food supplement with a formula specifically designed to temporarily attach to the inner wall of the stomach.

This innovative oral suspension is a blend of ozonized olive glycerides with a balanced blend of polysaccharides and magnesium carbonate. The attachment of this solution to the gastric mucosa is caused by the strong viscosity and special resistance of these polysaccharides to gastric digestion. They are also responsible for the high stability of the suspension and they allow a controlled release of ozone.

Why does is it effective?

• Germicidal and bactericidal effects The slow release of ozone (O3) destroys germs and bacteria through oxidation.

• Release of growth factors Substances important for cell development.

• Antioxidant effect Stimulates the main components of the enzymatic antioxidant system, such as:

superoxide dismutase, catalysis, and glutathione peroxidase.

Several published studies have shown that Ozone Therapy can be another effective tool in the prevention of various gastrointestinal disorders.

This is due to ozone´s induction methods (O3) which promote a rapid recovery of the gastric mucosa and consequently that of gastric and duodenal ulcers as well. The results of these studies show a lack of adverse effects and an absence of symptomology (pain).

Gastrointestinal Diseases and Helicobacter pylori Infection

• Several gastrointestinal disorders and diseases have been related to Helicobacter pylori.

The evolution of H. Pylori infection depends on many factors, including genotype, physiology and genetics of the bacterium, as well as environmental factors and diet.

Science continues to investigate the complexity of H. Pylori, looking for answers to understand why some infected people are asymptomatic, whilst others experience the infection in a symptomatic way.

Symptoms of a gastric disease (caused by the bacterium H. Pylori) arise in adults; however, contagion occurs in childhood.

This bacterium is present in more than half of the world's population, in underdeveloped countries, it affects 80% of the population, and in more developed countries, it affects 30% of the population.

Recently, researchers have confirmed the importance of treating Helicobacter Pylori infection in patients with gastrointestinal issues.

Clinical studies show that treatment of the infection prevents duodenal ulcer formation, extensive lesions, and recurrent gastric ulcers; it also prevents mucosa-associated lymphoid tissue lymphoma (MALT) and reduces the risk of developing gastric cancer in individuals with a greater predisposition.